Distinct from IFN-γ, which is pro-tumorigenic and stimulates melanoma progression, IFN-α has been extensively utilized in the clinic as an adjuvant treatment for melanoma patients at high risk of relapse after surgical resection. The gene discussed is IFNA1; the disease is melanoma.